Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Immunocore Holdings Plc ADR (IMCR)

Immunocore Holdings Plc ADR (IMCR)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
29.43 +0.80 (+2.79%) 04/02/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 29.43 unch (unch) 16:40 ET
Quote Overview for Wed, Apr 2nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
28.43
Day High
29.90
Open 28.43
Previous Close 28.63 28.63
Volume 633,300 633,300
Avg Vol 430,730 430,730
Stochastic %K 34.41% 34.41%
Weighted Alpha -47.11 -47.11
5-Day Change -0.04 (-0.14%) -0.04 (-0.14%)
52-Week Range 27.19 - 64.47 27.19 - 64.47
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,432,445
  • Shares Outstanding, K 50,033
  • Annual Sales, $ 310,200 K
  • Annual Income, $ -51,090 K
  • EBIT $ -70 M
  • EBITDA $ -66 M
  • 60-Month Beta 0.75
  • Price/Sales 4.79
  • Price/Cash Flow N/A
  • Price/Book 4.12

Options Overview Details

View History
  • Implied Volatility 58.04% ( -7.11%)
  • Historical Volatility 43.75%
  • IV Percentile 27%
  • IV Rank 16.98%
  • IV High 109.35% on 05/22/24
  • IV Low 47.55% on 03/27/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 110
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 3,569
  • Open Int (30-Day) 5,049

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.35
  • Number of Estimates 7
  • High Estimate -0.20
  • Low Estimate -0.48
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.19 +8.24%
on 03/11/25
Period Open: 29.37
31.64 -6.98%
on 03/20/25
+0.06 (+0.20%)
since 02/28/25
3-Month
27.19 +8.24%
on 03/11/25
Period Open: 29.82
33.93 -13.26%
on 01/27/25
-0.39 (-1.31%)
since 01/02/25
52-Week
27.19 +8.24%
on 03/11/25
Period Open: 63.48
64.47 -54.35%
on 04/03/24
-34.05 (-53.64%)
since 04/02/24

Most Recent Stories

More News
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates

Puma Biotechnology PBYI reported fourth-quarter 2024 adjusted earnings of 43 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company reported adjusted...

FOLD : 7.99 (+0.50%)
IMCR : 29.43 (+2.79%)
PBYI : 3.01 (+2.73%)
PCRX : 24.89 (+3.41%)
Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales

Shares of Bausch Health Companies Inc. BHC gained 2.36% after the company reported better-than-expected fourth-quarter results. Shares also gained 7.8% in aftermarket trading.Adjusted earnings per share...

IMCR : 29.43 (+2.79%)
PCRX : 24.89 (+3.41%)
BHC : 6.11 (-2.24%)
New Strong Buy Stocks for January 7th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Artivion, Inc. AORT: This medical device and tissue engineering company has seen the Zacks Consensus Estimate for its current year...

NN : 12.82 (+4.40%)
IMCR : 29.43 (+2.79%)
VERX : 37.02 (+2.61%)
EVER : 26.65 (+0.34%)
AORT : 25.05 (+1.54%)
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why

Shares of Puma Biotechnology, Inc. PBYI have rallied 24% in the past three months against the industry’s decline of 9.7%.The company’s sole marketed product, Nerlynx (neratinib), is approved for treating...

IMCR : 29.43 (+2.79%)
PBYI : 3.01 (+2.73%)
RHHBY : 39.3700 (-4.16%)
SPRO : 0.7060 (+1.73%)
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025

The biotech sector witnessed a see-saw performance in 2024. Though the year started on a positive note, those gains were erased in the second half due to disappointing third-quarter results, guidance cuts,...

ALLO : 1.4400 (+5.11%)
IMCR : 29.43 (+2.79%)
DAWN : 7.97 (+4.73%)
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term

Genomics companies analyze and interpret genetic information to uncover insights about genetic variations and disease mechanisms and develop tests, therapies and technologies to advance personalized medicine. Companies...

IMCR : 29.43 (+2.79%)
CRSP : 34.19 (+3.17%)
GLUE : 4.41 (-0.45%)
CSTL : 20.19 (+2.07%)
RIGL : 18.21 (+6.18%)
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis...

CORT : 83.81 (-8.83%)
IMCR : 29.43 (+2.79%)
CSTL : 20.19 (+2.07%)
SPRO : 0.7060 (+1.73%)
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up

Shares of Beam Therapeutics Inc. BEAM were up 5.5% on Dec. 6 after the company announced that it has appointed Sravan K. Emany as its new chief financial officer (CFO).He will assume his new role on Dec....

BEAM : 18.48 (+4.79%)
IMCR : 29.43 (+2.79%)
CSTL : 20.19 (+2.07%)
SPRO : 0.7060 (+1.73%)
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug

Stoke Therapeutics, Inc. STOK announced that the FDA has granted a Breakthrough Therapy designation to its investigational candidate, zorevunersen (STK-001), for the treatment of Dravet syndrome, a severe...

IMCR : 29.43 (+2.79%)
CSTL : 20.19 (+2.07%)
STOK : 6.60 (+5.94%)
SPRO : 0.7060 (+1.73%)
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug

Rezolute, Inc. RZLT announced that the FDA has granted an Orphan Drug Designation (“ODD”) to its lead pipeline candidate, ersodetug (RZ358), for the treatment of hypoglycemia caused by tumor hyperinsulinism...

IMCR : 29.43 (+2.79%)
RZLT : 3.02 (+3.42%)
CSTL : 20.19 (+2.07%)
SPRO : 0.7060 (+1.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Immunocore Holdings plc is a late-stage biotechnology company. It engages in development of a novel class of T cell receptor bispecific immunotherapies designed to treat diseases, including cancer, infectious and autoimmune disease. Immunocore Holdings plc is based in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 31.55
2nd Resistance Point 30.72
1st Resistance Point 30.08
Last Price 29.43
1st Support Level 28.61
2nd Support Level 27.78
3rd Support Level 27.14

See More

52-Week High 64.47
Fibonacci 61.8% 50.23
Fibonacci 50% 45.83
Fibonacci 38.2% 41.43
Last Price 29.43
52-Week Low 27.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades